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Abstract
We have previously determined that the HGF promoter can be transactivated by a combination of
activated Src and wild-type Stat3 in the mouse breast cell lines HC11 and SP1. To determine if this
pathway is of relevance for the human disease, a series of human breast and other human cells lines
were examined, and the status of key proteins in these cells determined. All of the human breast
cell lines exhibited strong transactivation by a combination of activated Src and Stat3. This
activation was dependent on a Stat3 recognition element present at nt-95. The exception was the
ErbB2 over-expressing cell line SK-BR-3 where Stat3 alone could transactivate HGF though Src
augmented this effect. Increased phosphorylation of Stat3 tyrosine 705 was also observed in this
line. Analysis of three ovarian cell lines revealed that Src/Stat3 expression was not able to activate
the HGF promoter in two of these lines (SKOV3 and IOSE-80PC). Src/Stat3 expression did activate
HGF transcription in OVCAR3 cells, but this effect was not mediated by the Stat3 site at nt-95.
Stat3 phosphorylation at tyrosine 705 was observed in IOSE-80PC cells, but was insufficient to
allow for activation of the HGF promoter. Human kidney (HEK293) and cervical carcinoma (HeLa)
cells were also not Src/Stat3 permissive, despite high levels of Stat3 phospho-Y705. These results
suggest that human breast cells are a uniquely permissive environment for HGF transactivation by
Src/Stat3 which may allow for the inappropriate activation of HGF transcription during the early
stages of breast transformation. This could lead to paracrine or autocrine activation of the Met
receptor in breast carcinoma cells.
Background
Hepatocyte Growth Factor (HGF) is a multi-functional
cytokine primarily expressed in mesenchymal cells. By
binding to its receptor Met, which is expressed on the sur-
face of epithelial cells, HGF regulates many cellular proc-
esses including growth, angiogenesis, migration,
morphogenesis, epithelial-mesenchymal transition and
cell survival [1,2]. HGF participates in normal mammary
development through tightly regulated paracrine signal-
ing, however aberrant regulation of the HGF/Met signal-
ing pathway is thought to contribute to tumorigenesis
[3,4]. In addition, we [5] and others [6-8] have previously
observed frequent over-expression of both HGF and Met
in invasive human breast carcinomas.
The increased activation of Src and Signal Transducer and
Activator of Transcription 3 (Stat3) proteins is associated
with breast tumorigenesis [9,10] as well as a number of
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other human cancers [11,12]. Both activated Src and Stat3
mediate signals downstream of the HGF/Met pathway
[13,14], and are key regulators of tumourigenic growth
and survival [15,16]. In addition, Stat3 activation by Src
induces specific gene regulation and is required for cell
transformation [14,17]. We have previously shown that
activated Src/Stat3 co-operativity enhances HGF transcrip-
tional activity and protein expression, and induces HGF-
dependent scattering in mammary epithelial cells [18,19].
We have also characterized a Src/Stat3 responsive region
on the HGF promoter identifying a Stat3 consensus bind-
ing site at nt-95 that has been demonstrated to be required
for HGF promoter activation by Src/Stat3 in mouse mam-
mary carcinoma cells [18]. Overall, these observations
suggest a model where positive feedback signals in the
HGF/Met Src/Stat3 axis contribute to the transformation
process.
The use of a murine system provides a useful model for
the study of breast cancer, however the phenomenon
observed in mouse mammary tumour cells has not been
assessed in a human model, which may not necessarily
recapitulate the disease in the same manner. Sequence
homology comparison showed that the nt-95 Stat3 bind-
ing site as well as the sequences flanking this region is
completely conserved between the mouse and human
HGF genes. We therefore investigated the mechanisms of
Src/Stat3 co-operativity and their interaction at the nt-95
site on the HGF promoter to activate HGF transcription in
a panel of human epithelial cell lines. We demonstrated
that human breast cells provide a permissive environment
for HGF/Met signaling, and that the Stat3 nt-95 binding
site is required to mediate the co-operative effects of Src/
Stat3 induced HGF transactivation. These findings suggest
a molecular mechanism that through co-operative SRC/
Stat3 signaling could activate an HGF/Met autocrine loop
in breast cancer cells.
Results and discussion
The ability of both Src and Stat3 to activate the HGF pro-
moter was assessed by co-transfection of a mouse HGF
proximal promoter construct into a variety of Src respon-
sive mouse and human epithelial cell lines. The proximal
promoter consisted of sequences from nt-274 to +29 of
the mouse HGF gene cloned upstream of the renilla luci-
ferase reporter gene, and shares approximately 83%
homology to that of human HGF (Figure 1A). In addition
to the wild-type reporter construct, we also generated a
point mutant which eliminates the Stat3 recognition site
located at nt-95. The Stat3 binding site, as well as the
sequences flanking this region are completely conserved
between the mouse and human genes.
Co-transfection of activated Src or Stat3 alone had no
effect on HGF promoter activity in mouse tumorigenic
SP1 (Figure 1B), and non-tumorigenic HC11 and EPH4
(Figure 1C, D) breast cell lines. In contrast, co-transfection
of both activated Src and Stat3 resulted in a 1.6 to 2.4-fold
induction of HGF promoter activity depending on the cell
line. This Src/Stat3 mediated HGF induction was severely
diminished upon mutation of the nt-95 site on the HGF
promoter, and indicates the necessity of this binding site
for Stat3 mediated HGF activation. These observations
extend our previous studies [18], investigating the activat-
ing functions of Src and Stat3 on HGF transcription in
mouse breast cancer cells. Western blot analysis character-
izing the patterns of endogenous expression of the pro-
teins involved in the HGF/Met signaling pathway across a
variety of epithelial cell lines indicate that the mouse
mammary carcinoma SP1 cell line endogenously
expresses high levels of HGF, while also expressing high
levels of activated Met as indicated by Met receptor phos-
phorylation (Figure 2). Furthermore, the SP1 cell line also
endogenously expresses high levels of activated Src and
Stat3 as determined by Src and Stat3 phosphorylation,
and is consistent with our previous findings which dem-
onstrated the use of the SP1 cell line as an appropriate
autocrine model for the study of co-operative Src/Stat3
signaling on HGF transcription in mice [19]. In contrast,
EPH4 cells expressed very low levels of HGF, and both
phosphorylated Met and Stat3. Detectable levels of HGF
and phosphorylated Stat3 expression were observed in the
HC11 cell line, however this was insufficient to cause
phosphorylation of Met in these cells. This indicates that
while tumourigenic SP1 cells may sustain a constitutively
active HGF/Met signaling pathway, non-tumourigenic
HC11 and EPH4 cells both represent a permissive envi-
ronment for HGF transactivation upon appropriate Src/
Stat3 activation.
We next assessed human breast cell lines for HGF respon-
siveness in the presence of activated Src and Stat3. Strong
Src and Stat3-dependent HGF promoter transactivation
was observed in non-tumorigenic 184-hTERT and
MCF10a breast cell lines (Figure 3A, B), as well as in the
malignant MCF-7 adenocarcinoma and T47-D ductal car-
cinoma breast cell lines (Figure 3C, D), ranging from a 4
to 10-fold induction. In the highly malignant human SK-
BR-3 adenocarcinoma breast cell line, transfection of
Stat3 alone was sufficient to activate the HGF promoter by
10-fold, however upon co-transfection of both activated
Src and Stat3, a 20-fold induction of HGF promoter trans-
activation was observed (Figure 3E). HGF induction was
mediated through the nt-95 site on the HGF promoter
since this activation was severely diminished upon its
mutation in all the human breast cell lines surveyed.
Endogenous Src expression appears to be elevated in SK-
BR-3 compared to MCF-7 and T47-D cells as indicated by
western blot analysis. Although only moderate levels ofMolecular Cancer 2007, 6:69 http://www.molecular-cancer.com/content/6/1/69
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Src/Stat3 mediated HGF promoter transactivation in mouse epithelial breast cell lines Figure 1
Src/Stat3 mediated HGF promoter transactivation in mouse epithelial breast cell lines. A DNA sequence align-
ment between the mouse HGF proximal promoter spanning from nt-274 to +29 is shown with the comparable region of the 
human gene (A). The Stat3 site at nt-95 is boxed and the transcriptional start site is indicated by an arrow. The 0.3 HGF-Renilla 
or -95 M 0.3 HGF-Renilla mouse proximal promoters were co-transfected with either activated Src or Stat3 alone, or in com-
bination in: mouse mammary carcinoma SP1 cells (B), non-tumorigenic mouse mammary HC11 cells (C), and non-tumorigenic 
mouse mammary EPH4 cells (D). 48 hours post-transfection, cells were lysed and assayed for dual-luciferase activity. Values 
were normalized using a CMV-Luc internal control and are presented as fold induction relative to the empty vector (EV) for 
0.3 HGF-Renilla. Asterisks indicate a significant increase in HGF promoter activity compared to the 0.3 HGF-Renilla empty vec-
tor control (P = 0.001*, P = 0.0005** using a Student's T-test). Transfections were repeated three times and values represent 
average results of triplicate samples +/- SD.
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Mouse -294 ggagccacaaggatctggagctccagcttccaaattgcagctggcctcgg
           ||||||||  ||||||||||||||||||||||||||| |||||||||| |
Human      ggagccactgggatctggagctccagcttccaaattgaagctggcctcag
Mouse -243 gccaggtgacctttgctttgtaagtttctttc-------tggg---aggg
           |||||||||| ||| |||||||||||||||||       ||||    |||
Human      gccaggtgactttt-ctttgtaagtttctttcctaagcgtggggttgggg
Mouse -203 gga----gtgtgtggaggggagagctgggatctgt----tgcttgttggg
           |||    | |  ||| ||||   || |||||||||    ||| |||||  
Human      ggaggcggggaatggggggggttgcagggatctgtttggtgc-tgttgaa
Mouse -161 gggggggggggttgaggaaaggaaggggctggaagagagtaaagggctgt
           ||||||| | | ||||||||||| ||||||||||||||||||||||||||
Human      gggggggcgag-tgaggaaaggagggggctggaagagagtaaagggctgt
Mouse -109 tgttaaacagtttcttaccgtaagagggagttcagacctagatctttcca
           ||||||||||||||||||||||||||||||||||||||||||||||||||
Human      tgttaaacagtttcttaccgtaagagggagttcagacctagatctttcca
Mouse  -59 gttaatcacacaacaaacttagctcatcgcaat-aaaagcagctcagaac
           ||||||||||||||||||||||||||||||||| |||||||||||||| |
Human      gttaatcacacaacaaacttagctcatcgcaataaaaagcagctcagagc
    
Mouse  -12 cgaccgg----ttt--gc----------aacaggattctttcagcccggc
           |||| ||    |||  ||          ||||||||||||||| || |||
Human      cgactggctcttttaggcactgactccgaacaggattctttcacccaggc
Mouse  +25 atctc +29
           |||||                                             
Human      atctc
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Src Y418 phosphorylation were detected in SK-BR-3 cells
(Figure 2), it is well established that these cells possess
increased Src activity as a result of ErbB2 oncogene over-
expression [20,21]. However, ErbB2 signaling in human
breast cancer has been associated primarily with Src Y215
phosphorylation [22,23]. Therefore the apparent Src-
independent activation of the HGF promoter in SK-BR-3
cells may be attributed to high levels of endogenously
expressed Src pY215. SK-BR-3 cells also express high
endogenous levels of activated Stat3 (Figure 2), though
Stat3-dependent activation of the HGF promoter and an
effect of both Src and Stat3 together is still observed. This
finding indicates that the Src/Stat3 mediated activation of
HGF requires levels of activated Stat3 expression above
those of endogenously expressed Stat3. Interestingly, all
of the human breast cell lines have similar high levels of
Stat3, but HGF stimulation requires both activated Src
and over-expression of Stat3. In fact, tissue microarray
analysis of breast cancer tissues show elevated levels of
both phosphorylated Y705-Stat3 and S727-Stat3 in 35%
[24] and 62% [25] of cases respectively, indicating that
the activation of Stat3 may play a key role in breast cancer
oncogenesis. In addition, levels of both activated Stat3
and Src have been shown to be significantly higher in
invasive breast carcinoma tissues suggesting the impor-
tant role of elevated Src and Stat3 protein expression in
malignant breast cancer progression [10].
Met receptor expression was widely observed in all cell
lines with the exception of human MCF-7 and T47-D
breast cell lines (Figure 2). It has previously been pro-
posed that the co-operative effects of activated Src/Stat3
Endogenous expression and activity of HGF/Met signaling proteins in mouse and human epithelial cell lines Figure 2
Endogenous expression and activity of HGF/Met signaling proteins in mouse and human epithelial cell lines. 
Endogenous protein expression and activation levels of HGF, Met, Src and Stat3 were characterized in mouse and human epi-
thelial cell lines by western blot analysis. Whole cell lysates collected from the indicated cell lines were normalized and 
resolved on a reducing SDS-PAGE gel. Western blot analysis was performed using antibodies probing for the indicated pro-
teins (arrows point to relevant band). γ-Tubulin was used as a loading control to normalize for overall protein concentration, 
and recombinant HGF (rHGF) served as a control for HGFα migration.
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Src/Stat3 mediated HGF promoter transactivation in human epithelial breast cell lines Figure 3
Src/Stat3 mediated HGF promoter transactivation in human epithelial breast cell lines. The 0.3 HGF-Renilla or -
95 M 0.3 HGF-Renilla mouse proximal promoters were co-transfected with either activated Src or Stat3 alone, or in combina-
tion in: human non-tumorigenic 184-hTERT (A) and MCF10a breast cells (B), human MCF-7 adenocarcinoma breast cells (C), 
human T47-D ductal carcinoma breast cells (D), and human SK-BR-3 adenocarinoma breast cells (E). 48 hours post-transfec-
tion, cells were lysed and assayed for dual-luciferase activity. Values were normalized using a CMV-Luc internal control and are 
presented as fold induction relative to the empty vector (EV) for 0.3 HGF-Renilla. Asterisks indicate a significant increase in 
HGF promoter activity compared to the 0.3 HGF-Renilla empty vector control (P = 0.001*, 0.0003**, 0.0005*** using a Stu-
dent's T-test). Transfections were repeated three times and values represent average results of triplicate samples +/- SD.
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induced HGF expression result in the formation of an
HGF autocrine loop, whereby epithelial cells secrete HGF
and activate their own Met receptors maintaining a state
of sustained HGF activation leading to tumorigenesis [5].
While the absence of Met receptor in these cells suggests
that such an autocrine loop is not currently operating, this
process may have played a role in the origin of these
tumours. It is also possible that HGF-expressing carci-
noma cells could "recruit" adjacent Met positive pre-
malignant or malignant cells thereby stimulating these
cells to invade.
A number of other well established non-breast human
lines such as ovarian, cervical and embryonic kidney epi-
thelial cell lines were also surveyed to assess HGF respon-
siveness in the presence of activated Src and Stat3. Co-
transfection of activated Src and Stat3 induced a 4-fold
activation of the HGF promoter in the tumorigenic ovar-
ian OVCAR3 cell line, however this effect does not appear
to occur via the nt-95 site since mutation of this site
showed no inhibitory effect on HGF induction (Figure
4A). Western blot analysis indicates that the OVCAR3 cell
line expresses relatively low levels of endogenous acti-
vated Src and Stat3, and they do not appear to over-
express any of the proteins involved in the HGF/Met sign-
aling pathway (Figure 2). The observed activation of both
the wild-type and mutated HGF promoters may reflect the
activation of other transcription factors by Src/Stat3 which
in turn activate the HGF promoter through an alternate
site.
It is interesting that this alternate pathway of HGF tran-
scriptional activation was only observed in one ovarian
cell line suggesting that a unique HGF related pathway
may exist in these cells. The OVCAR3 cell line was the only
line to exhibit this characteristic as ovarian tumorigenic
SKOV3, non-tumorigenic IOSE-80PC and HEK293 kid-
ney adenocarcinoma cell lines did not support transacti-
vation of the HGF promoter upon co-transfection of
activated Src and Stat3 (Figure 4B–D). Similarly, transac-
tivation of the HGF promoter was not observed upon co-
transfection of activated Src and Stat3 in HeLa cervical car-
cinoma cells (Figure 4E) despite the high levels of acti-
vated Stat3 and Met expressed in this cell line (Figure 2).
This finding parallels the expression patterns observed in
SP1 cells which are Src/Stat3 responsive indicating that
over-expression of these proteins is not sufficient for HGF
transactivation in HeLa cells. This suggests that breast cells
must possess a mechanism which produces a permissive
environment for Src/Stat3 mediated HGF transcriptional
activation.
Conclusion
We observed activated Src/Stat3 mediated HGF transacti-
vation in both malignant and non-tumorigenic human
breast cell lines but not in human non-breast epithelial
cell lines. This suggests that the activated Src/Stat3 medi-
ated effects are tissue-specific with breast cell lines provid-
ing a permissive environment for the HGF/Met signaling
pathway. Furthermore, in addition to requiring the over-
expression of both activated Src and Stat3 to induce HGF
transcription, the Stat3 nt-95 binding site on the HGF pro-
moter is also a necessary requirement to mediate the co-
operative Src/Stat3 transactivation of the HGF promoter
in human breast cells. These studies suggest that the HGF/
Met Src/Stat3 signaling loop may be a potential treatment
target and/or a prognostic indicator for invasive breast
cancer.
Methods
Mutagenesis and cloning
0.3 HGF-Renilla and -95 M 0.3 HGF-Renilla constructs
were generated by PCR using 0.5 HGF-Luc and -95 M 0.5
HGF-Luc constructs [18] respectively as HGF template
DNA. The HGF 5' Forward (5'-GGGCTCGAG-
GGAGCCACAAGGATC-3') and HGF 3' Reverse (5'-
GGGAAGCTTGAGATGCCGGGCTG-3') primers were used
to generate the 0.3 HGF fragment were inserted into the
pRL-null vector using XhoI and HindIII restriction sites.
Transient transfection and dual luciferase assay
Mouse and human cells were cultured as described in
Additional file 1. SP1 and HC11 cell line transfections
were performed using the LipofectAMINE Plus™ system
(Invitrogen™) according to manufacturer's protocols.
Cells were seeded in 12-well plates at cell densities indi-
cated [See Additional file 1], incubated overnight in com-
plete growth medium, and transfected with a total of 1 µg
of DNA. MCF10a cell line transfections were performed
using ESCORT V Transfection Reagent (Sigma Aldrich,
Oakville, ON, Canada) according to manufacturer's pro-
tocols. Cells were seeded in 12-well plates at cell densities
indicated [See Additional file 1], incubated overnight in
complete growth medium, and transfected with a total of
1.4 µg of DNA. All other cell line transfections were per-
formed using FuGene 6 Transfection Reagent (Roche
Applied Sciences, Laval, QC, Canada) according to manu-
facturer's protocols. Cell lines were seeded in 12-well
plates at cell densities indicated [See Additional file 1],
incubated overnight in complete growth medium, and
transfected with a total of 250 ng of DNA.
For luciferase assays, cells were lysed in 1× Passive Lysis
Buffer (Promega) 48 hours post-transfection, and Dual-
Luciferase™ Reporter assays (Promega) were performed
according to manufacturer's protocols using an EG&G
Berthold microplate luminometer. All luciferase transfec-
tions were normalized to a corresponding CMV-luciferase
internal control (Promega) to adjust for variations in
transfection efficiency between different cell lines.Molecular Cancer 2007, 6:69 http://www.molecular-cancer.com/content/6/1/69
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Src/Stat3 mediated HGF promoter transactivation in human non-breast epithelial cell lines Figure 4
Src/Stat3 mediated HGF promoter transactivation in human non-breast epithelial cell lines. The 0.3 HGF-Renilla 
or -95 M 0.3 HGF-Renilla mouse proximal promoters were co-transfected with either activated Src or Stat3 alone, or in com-
bination in: human ovarian tumorigenic OVCAR3 (A) and SKOV3 cells (B), human ovarian non-tumorigenic ovarian IOSE-80PC 
cells (C), human embryonic kidney HEK293 adenocarcinoma cells (D), and human cervical carcinoma HeLa cells (E). 48 hours 
post-transfection, cells were lysed and assayed for dual-luciferase activity. Values were normalized using a CMV-Luc internal 
control and are presented as fold induction relative to the empty vector (EV) for 0.3 HGF-Renilla. Asterisks indicate a signifi-
cant increase in HGF promoter activity compared to the 0.3 HGF-Renilla empty vector control (P = 0.0005* using a Student's 
T-test). Transfections were repeated three times and values represent average results of triplicate samples +/- SD.
SKOV3
EV
Src
Stat3
Src+Stat3
EV
Src
Stat3
Src+Stat3
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00 0.3HGF-Renilla
-95M 0.3HGF-Renilla
H
G
F
 
P
r
o
m
o
t
e
r
 
A
c
t
i
v
i
t
y
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
B.
IOSE-80PC
EV
Src
Stat3
Src+Stat3
EV
Src
Stat3
Src+Stat3 0.0
0.5
1.0
1.5
2.0 0.3HGF-Renilla
-95M 0.3HGF-Renilla
H
G
F
 
P
r
o
m
o
t
e
r
 
A
c
t
i
v
i
t
y
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
C.
HEK293
EV
Src
Stat3
Src+Stat3
EV
Src
Stat3
Src+Stat3 0.00
0.25
0.50
0.75
1.00
1.25
1.50
0.3HGF-Renilla
-95M 0.3HGF-Renilla
H
G
F
 
P
r
o
m
o
t
e
r
 
A
c
t
i
v
i
t
y
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
D.
HeLa
EV
Src
Stat3
Src+Stat3
EV
Src
Stat3
Src+Stat3 0.00
0.25
0.50
0.75
1.00
1.25
1.50
0.3HGF-Renilla
-95M 0.3HGF-Renilla
H
G
F
 
P
r
o
m
o
t
e
r
 
A
c
t
i
v
i
t
y
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
E.
OVCAR3
EV
Src
Stat3
Src+Stat3
EV
Src
Stat3
Src+Stat3 0
1
2
3
4
5 0.3HGF-Renilla
-95M 0.3HGF-Renilla
H
G
F
 
P
r
o
m
o
t
e
r
 
A
c
t
i
v
i
t
y
(
F
o
l
d
 
I
n
d
u
c
t
i
o
n
)
A.
*
*Molecular Cancer 2007, 6:69 http://www.molecular-cancer.com/content/6/1/69
Page 8 of 9
(page number not for citation purposes)
Western Blotting
Cells were washed twice with 1× PBS and lysed in RIPA
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% Sodium deoxycholate, 1 µg/mL
Trasylol, 1 µg/mL Leupeptin, 1 mM DTT, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM NaF, 1 mM Na3VO4, and
20 mM β-glycerophosphate). Collected lysates were incu-
bated for 15 minutes at 4°C and subjected to protein
determination using a Bio-Rad Dc protein assay kit (Bio-
Rad, Mississauga, ON, Canada). Normalized protein lev-
els were resolved on an 8 or 10% reducing SDS-PAGE gel
(with 3% β-2-mercaptoethanol in loading buffer), and
transferred onto PVDF membranes (Millipore). Separate
membranes were probed with the indicated primary anti-
bodies, anti-Stat3 (#9132), phospho-specific anti-
Stat3(pY705) (#9131), and anti-Met(pY1234/1235)
(#3126) (Cell Signaling Technology, Beverly, MA, USA),
anti-human Met (C12), anti-mouse Met (B2), anti-Src
(B12), anti-HGFα (H-145) (Santa Cruz Biotechnology
Inc, Santa Cruz, CA, USA), phospho-specific anti-
Src(pY418) (#44-660A1) (Biosource International, Burl-
ington, ON, Canada), and anti-γ-tubulin (GTU-88)
(Sigma Aldrich, Oakville, ON, Canada). Immune com-
plexes were detected using horse-radish peroxidase
(HRP)-labelled anti-rabbit or anti-mouse IgG (Amersham
Biosciences, Baie d'Urfè, QC, Canada) followed by
enhanced chemi-luminescence (Perkin Elmer, Wood-
bridge, ON, Canada).
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